-+ 0.00%
-+ 0.00%
-+ 0.00%

Ladenburg Thalmann Initiates Coverage On Inhibikase Therapeutics with Buy Rating, Announces Price Target of $4

Benzinga·03/04/2026 12:53:52
Listen to the news
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Inhibikase Therapeutics (NASDAQ:IKT) with a Buy rating and announces Price Target of $4.